Placental Senescence in Peripartum Cardiomyopathy
围产期心肌病中的胎盘衰老
基本信息
- 批准号:10716493
- 负责人:
- 金额:$ 47.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAgingAutomobile DrivingBiologicalBiological AgingBiological MarkersBiological ModelsBiological ProcessBiologyBiology of AgingCardiacCardiac MyocytesCardiovascular DiseasesCardiovascular PhysiologyCellsClinicalCoculture TechniquesDataDevelopmentDiseaseEtiologyExperimental ModelsFunctional disorderGeneticGenetic Predisposition to DiseaseHealthHeartHeart DiseasesHeart failureHumanHuman bodyHypertrophyIncidenceIndividualInfectionInterventionLate pregnancyLongevityMalignant NeoplasmsMetabolicMissionModelingMusMyocardial dysfunctionNational Heart, Lung, and Blood InstituteOrganParabiosisPathogenesisPathologicPathway interactionsPhenotypePlacentaPostpartum PeriodPre-Clinical ModelPre-EclampsiaPregnancyProcessProteinsProteomeProteomicsPublic HealthResearchRisk FactorsRoleSerumSeveritiesStudy modelsSyndromeSystemTechnologyTherapeuticTissuesUnited States National Institutes of HealthVentricular RemodelingWomanWorkactivin Acase controlcohortexperimental studygain of functionheart functionhemodynamicshuman genomicsimplantationimprovedin vitro Modelin vivoinnovationinsightloss of functionmetabolic phenotypenovelparacrineperipartum cardiomyopathypharmacologicresearch studysecretory proteinsenescencetargeted treatmenttherapeutic developmenttranscriptome sequencingtranslational potentialyoung woman
项目摘要
PROJECT SUMMARY/ABSTRACT
Peripartum cardiomyopathy (PPCM) is a rare form of heart failure (HF) that occurs in women during late
pregnancy to the early postpartum period. Although PPCM incidence is increasing, the etiology of this syndrome
remains unclear and limited treatments are available. A “2-hit” mechanism— in which 1) an unrecognized genetic
predisposition for HF is unmasked by 2) a surge of deleterious circulating factors in late pregnancy—is the
leading hypothesis in PPCM. A fundamental gap in our understanding of PPCM is what the core pathobiology
driving this “2nd hit” is. Our group recently profiled the circulating proteome of women with PPCM or preeclampsia
(a major PPCM risk factor) to gain insights into their shared secretory pathophysiology. This paradoxically
identified the senescence-associated secretory phenotype (SASP), a marker of biological aging, as the most
highly upregulated biological process in these young women. Our preliminary data in human cohorts and
experimental models has identified strong associations between senescence biology and cardiac dysfunction
and HF severity in PPCM, and ultimately led us to a novel hypothesis that accelerated placental senescence is
the elusive root cause of the “2nd hit” in PPCM pathophysiology. The placenta, whose lifespan is limited to ~40
weeks, can be viewed as the fastest aging organ in the human body and notably becomes markedly senescent
by late pregnancy. Our objective here is to prove causality of placental senescence in PPCM. Here we propose
three integrated Specific Aims that incorporate rigorous gain- and loss-of-function experiments to definitively
answer this question. In Aim 1, we will use parabiosis and heterotopic placental implantation to determine if the
senescent placenta secretome is sufficient to induce cardiac dysfunction in PPCM-prone mice. In Aim 2, we will
incorporate pharmacological and genetic senolytic approaches to determine if placental senescence is
necessary in PPCM pathophysiology. Lastly, in Aim 3, we will systematically identify novel placenta-derived
senescence-associated secretory factors that induce pathologic cardiomyocyte hypertrophy, independent of
hemodynamic effects. This will integrate comprehensive functional, structural, and metabolic phenotyping with
proteomic and RNAseq profling in an ex vivo model system of human cardiomyocyte-placental crosstalk. Our
approach combines innovative hypotheses, state-of-the-art technology, and unique experimental strategies. The
proposed research is significant because it is expected to provide important new mechanistic insights into this
poorly understood HF syndrome that could fundamentally change the framework by which we approach cardiac
remodeling in pregnancy. The translational potential of this work is highlighted by our focus on secretory proteins
that can be targeted for therapeutic development, and could potentially be relevant to a broader spectrum of HF
syndromes associated with senescence (e.g. aging, cancer). Given our group’s expertise in aging biology,
cardiovascular physiology, and experimental models of HF, along with the expertise of our collaborators in
PPCM, preeclampsia, and human genomics, we are well equipped to complete the proposed research study.
项目概要/摘要
围产期心肌病 (PPCM) 是一种罕见的心力衰竭 (HF),发生于女性产后晚期。
尽管 PPCM 的发病率正在增加,但该综合征的病因仍不清楚。
仍不清楚,可用的治疗方法有限——其中 1) 未被识别的遗传。
2) 妊娠晚期有害循环因子的激增揭示了心力衰竭的易感性——是
PPCM 的主要假设是我们对 PPCM 理解的一个根本差距是核心病理学。
推动这一“第二次打击”的是我们的小组最近对患有 PPCM 或先兆子痫的女性的循环蛋白质组进行了分析。
(一个主要的 PPCM 风险因素)来深入了解他们共同的分泌病理生理学。
确定了衰老相关的分泌表型(SASP),这是生物衰老的标志,是最重要的
我们在人类队列中的初步数据和这些年轻女性的生物过程高度上调。
实验模型已确定衰老生物学与心脏功能障碍之间的密切关联
和 PPCM 中的 HF 严重程度,并最终使我们得出一个新的假设:加速胎盘衰老是
PPCM 病理生理学中“第二次打击”的难以捉摸的根本原因是胎盘,其寿命仅限于 40 岁左右。
几周,可以被视为人体衰老最快的器官,并且明显衰老
我们的目标是证明 PPCM 中胎盘衰老的因果关系。
三个综合的具体目标,其中结合了严格的功能获得和丧失实验,以明确
在目标 1 中,我们将使用联体共生和异位胎盘植入来回答这个问题。
在目标 2 中,衰老胎盘分泌组足以诱发 PPCM 小鼠的心脏功能障碍。
结合药理学和遗传衰老方法来确定胎盘衰老是否与
最后,在目标 3 中,我们将系统地鉴定新型胎盘来源。
衰老相关的分泌因子可诱导病理性心肌细胞肥大,独立于
这将整合全面的功能、结构和代谢表型。
人类心肌细胞-胎盘串扰的离体模型系统中的蛋白质组学和 RNAseq 分析。
该方法结合了创新假设、最先进的技术和独特的实验策略。
拟议的研究意义重大,因为预计它将为此提供重要的新机制见解
人们对心衰综合征知之甚少,它可能从根本上改变我们处理心脏病的框架
我们对分泌蛋白的关注凸显了这项工作的转化潜力。
可以作为治疗开发的目标,并且可能与更广泛的心力衰竭相关
鉴于我们团队在衰老生物学方面的专业知识,与衰老相关的综合征(例如衰老、癌症)。
心血管生理学和心力衰竭的实验模型,以及我们合作者在以下方面的专业知识
PPCM、先兆子痫和人类基因组学,我们有能力完成拟议的研究。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Aging in Heart Failure: Embracing Biology Over Chronology: JACC Family Series.
心力衰竭中的衰老:拥抱生物学而不是时间顺序:JACC 家庭系列。
- DOI:10.1016/j.jchf.2024.02.021
- 发表时间:2024-03-21
- 期刊:
- 影响因子:0
- 作者:Parag Goyal;Mathew S. Maurer;Jason Roh
- 通讯作者:Jason Roh
Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia.
循环心血管蛋白与妊娠高血压和先兆子痫的遗传关联。
- DOI:
- 发表时间:2024-03-01
- 期刊:
- 影响因子:24
- 作者:Schuermans, Art;Truong, Buu;Ardissino, Maddalena;Bhukar, Rohan;Slob, Eric A W;Nakao, Tetsushi;Dron, Jacqueline S;Small, Aeron M;Cho, So Mi Jemma;Yu, Zhi;Hornsby, Whitney;Antoine, Tajmara;Lannery, Kim;Postupaka, Darina;Gray, Kathryn J;Yan, Q
- 通讯作者:Yan, Q
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JASON DAVID ROH其他文献
JASON DAVID ROH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JASON DAVID ROH', 18)}}的其他基金
Activin type II receptor activity in age-related frailty and heart failure
激活素 II 型受体活性在年龄相关的衰弱和心力衰竭中的作用
- 批准号:
9811610 - 财政年份:2019
- 资助金额:
$ 47.63万 - 项目类别:
Activin type II receptor activity in age-related frailty and heart failure
激活素 II 型受体活性在年龄相关的衰弱和心力衰竭中的作用
- 批准号:
9981603 - 财政年份:2019
- 资助金额:
$ 47.63万 - 项目类别:
Activin type II receptor activity in age-related frailty and heart failure
激活素 II 型受体活性在年龄相关的衰弱和心力衰竭中的作用
- 批准号:
10433864 - 财政年份:2019
- 资助金额:
$ 47.63万 - 项目类别:
相似国自然基金
角质形成细胞源性外泌体携载miR-31调控成纤维细胞ERK通路抗皮肤老化的作用机制
- 批准号:82373460
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
塑料光老化介导的微(纳)塑料形成和光解产物释放对雄性生殖内分泌的干扰研究
- 批准号:22376195
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
东北黑土中农膜源微塑料冻融老化特征及其毒性效应
- 批准号:42377282
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
温度作用下CA砂浆非线性老化蠕变性能的多尺度研究
- 批准号:12302265
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
苯乙烯-丁二烯共聚物力化学老化的自由基捕获光环加成协同修复机制
- 批准号:22303065
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Interrogating the role of m6A mRNA methylation in the aging of the β-cell and diabetes
探讨 m6A mRNA 甲基化在 β 细胞衰老和糖尿病中的作用
- 批准号:
10644215 - 财政年份:2023
- 资助金额:
$ 47.63万 - 项目类别:
Novel mechanisms of muscle and bone loss with HIV infection, antiretroviral therapy, and aging.
HIV 感染、抗逆转录病毒治疗和衰老导致肌肉和骨质流失的新机制。
- 批准号:
10696502 - 财政年份:2023
- 资助金额:
$ 47.63万 - 项目类别:
Loss of transcriptional homeostasis of genes lacking CpG islands during aging
衰老过程中缺乏 CpG 岛的基因转录稳态丧失
- 批准号:
10814562 - 财政年份:2023
- 资助金额:
$ 47.63万 - 项目类别:
Targeting P21 positive senescent cells for alleviating TMJ degeneration
靶向 P21 阳性衰老细胞减轻 TMJ 变性
- 批准号:
10892710 - 财政年份:2023
- 资助金额:
$ 47.63万 - 项目类别:
Multiscale modeling of spatiotemporal evolution in Barrett's esophagus
巴雷特食管时空演化的多尺度建模
- 批准号:
10659649 - 财政年份:2023
- 资助金额:
$ 47.63万 - 项目类别: